Volume 13, Number 4 (July 2022)

Continuing Education Information: Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care

Introduction

Advances in the diagnosis and management of multiple myeloma (MM) and other plasma cell disorders such as AL amyloidosis and Waldenström macroglobulinemia (WM) continue to evolve rapidly. Over the past several years, there have been sign...

A Focus on Newly Diagnosed Multiple Myeloma

Multiple myeloma (MM) is an incurable plasma cell disorder that affects nearly 35,000 people annually. Over 149,000 individuals are estimated to live in the United States with MM. Research has generated a greater understanding of the pat...

A Focus on Relapsed Multiple Myeloma

Multiple myeloma (MM) is a relapsing disease for many patients with multiple myeloma. At relapse, patients have many options for treatment once disease has progressed. Advanced practitioners are well suited to set expectations for ongoin...

A Focus on Special Populations in Relapsed Multiple Myeloma

The overall care of patients with multiple myeloma can present similar challenges. However, disparities in health care require that providers consider each individual’s unique circumstances. Disparities based on ethnic/racial group, reli...

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

Significant strides have been made in the management of patients living with myeloma. However, patients with multiply relapsed or refractory multiple myeloma (MM) have a shorter overall survival; therefore, new treatments with novel mech...

A Focus on Waldenström Macroglobulinemia and AL Amyloidosis

Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma that is characterized by the overproduction of an IgM monoclonal protein. It may cause adenopathy, hepatomegaly, splenomegaly, as well as other disease-related complicati...